Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

IMV Inc IMVIF

Healthcare Biotechnology
IMV Inc. is a Canada-based company. The Company has no business operations.


GREY:IMVIF - Post by User

IMV Inc
Bullboard Posts
User Avatar Image
(17)
•••
Post by antisenseon May 29, 2020 9:38am
211 Views
Post# 31086918

Something I always wondered with this...

Something I always wondered with this...Is anyone else curious why IMV went the route or stayed the course of treating extrememly sick or treatment saturated patients?  I understand the need at first but keeping in mind this is a vaccine would it not make sense now that the MOA and safety profile is clearly established to use this VACCINE on healthy individuals and test to see if this VACCINE PREVENTS ovarian cancer.  I mean isn't this the whole point of a vaccine vs immunotherapy.  I think this company uses these two terms interchangeably which is a mistake IMO.  

Isn't it time for a large >1000 patient cohert in healthy females AT RISK of ovarian cancer?

Just curious what other posters thought about this...
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities